CTRI/2024/03/064051
Recruiting
未知
Exclusion of pre-treatment biopsy in children with unilateral renal tumours whoundergo delayed surgery: A prospective study - EBRT study (Exclusion of Biopsy in Renal Tumours)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C790- Secondary malignant neoplasm of kidney and renal pelvis
- Sponsor
- A
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients of ages 6 months\-10 years with the diagnosis of unilateral renal tumours on clinical and radiological examination, undergoing delayed surgery (after neo\-adjuvant chemotherapy) at the paediatric onco\-surgical without a diagnostic biopsy after informed consent during study period.
Exclusion Criteria
- •1\. Patients with renal tumours which are either planned for operation upfront or are bi\-lateral will be excluded from the study. Upfront nephrectomy was performed in the absence of one or more imaging based high risk features perinephric spread or adjacent organ infiltration, tumors crossing the midline, intravascular thrombus, and extensive adenopathy.
- •2\. Renal tumours with atypical features: age more than 10 years, uncertain renal origin, atypical metastases: bones or CNS (both at any age).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-PLOctapharma AG50
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-001785-17-CZOctapharma AG60
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-001785-17-FROctapharma AG60
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 17.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-001785-17-GBOctapharma AG49
Active, not recruiting
Not Applicable
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-ROOctapharma AG50